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SHORT COMMUNICATION 
 
 
Lack of association between MTHFR gene polymorphisms and 
response to methotrexate treatment in Pakistani patients with 
rheumatoid arthritis 
 
 
Mohammad Perwaiz Iqbal*1, Azra Arif Ali2, Naseema Mehboobali1 and Khalida Iqbal1 
1Departments of Biological & Biomedical Sciences and 2Medicine, Aga Khan University, Stadium Road, Karachi, Pakistan 
 
 
Abstract: Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms have been reported to be associated with 
response to methotrexate (MTX) in certain populations of patients with rheumatoid arthritis (RA). This study aims at 
investigating any relationship of two single nucleotide polymorphisms (SNPs) in MTHFR gene, C677T and A1298C 
with response to therapy with MTX in Pakistani RA patients. Allelic frequencies of the two polymorphisms (C677T and 
A1298C) were determined in 67 RA patients (9 males and 58 females; mean age 42.87±13.5 years) who had previously 
participated in a prospective clinical trial. Fifty-one patients had received MTX and were followed up for response up to 
6 months. Genotyping of the two MTHFR polymorphisms was carried out using PCR-RFLP, while fasting concentration 
of plasma homocysteine was determined using a kit method. Twenty-eight patients were found to be “good responders”, 
while twenty-three were “poor responders”. MTHFR 1298C and MTHFR 677T alleles’ frequencies in “good responders” 
were not different from frequencies in “poor responders” (0.574 vs. 0.521; p=0.6 and 0.197 vs. 0.196; p=0.75, 
respectively). Plasma homocysteine levels in female RA patients were significantly higher compared to general 
population in Karachi (13.1±6.7 µmol/l vs. 11.4±5.3 µmol/l; p<0.001). MTHFR C677T and A1298C polymorphisms are 
not associated with response to MTX in a population of Pakistani RA patients. 
  
Keywords: Gene polymorphism; Methylenetetrahydrofolate reductase; MTHFR C677T; MTHFR A1298C; 
Methotrexate; Pharmacogenomics; Rheumatoid arthritis; Response to methotrexate 
 
INTRODUCTION 
  
Methotrexate (MTX) is a commonly used disease 
modifying antirheumatic drug in treating rheumatoid 
arthritis (RA) patients. However, the efficacy of this drug 
in RA varies from one population to another. It has also 
been reported that nearly one-third of RA patients 
discontinue this drug because of its adverse reactions 
(Hider et al., 2007). Studies carried out mostly in the 
developed countries have shown two single nucleotide 
polymorphisms (SNPs) in methylenetetrahydrofolate 
reductase (MTHFR) to be pharmacogenomic markers of 
MTX toxicity (Urano et al., 2002; Berkun et al., 2004). A 
meta-analysis of MTHFR polymorphisms influencing 
MTX toxicity showed an association of 677C>T 
polymorphism with adverse reactions of MTX (Fisher et 
al., 2009). However, another recent meta-analysis showed 
no association of both C677T and A1298C 
polymorphisms with MTX toxicity (Owen et al., 2013). 
This indicates that response to MTX therapy in RA 
patients varies from one population to another. Since no 
study has been carried out to investigate the association of 
MTHFR gene polymorphisms and response to MTX in 
Pakistani RA patients, we embarked on carrying out such 
a study. Therefore, the objective was to find out any 
relationship of these two SNPs of MTHFR with response 
to MTX therapy in a population of RA patients visiting a 
tertiary-care hospital in Karachi. 
  
PATIENTS AND METHODS 
  
Allele frequencies of MTHFR C677T and MTHFR 
A1298C polymorphisms were determined in sixty-seven 
adult patients (58 females; 9 males; mean age 42.87±13.5 
years) visiting the Rheumatology Clinic of the Aga Khan 
University Hospital who had participated in a prospective 
study for assessing the response to MTX therapy. These 
patients were diagnosed to have RA on the basis of 
criteria described by the American Rheumatism 
Association for RA. Fifty-one patients received MTX, 15-
20 mg/week and were clinically assessed every month for 
a period of six months (Ali et al., 2006). Assessment of 
the clinical response to MTX therapy was based on 
criteria adopted by O’ Dell et al., (1998). After 6 months, 
those patients having fifty percent or more reduction in 
erythrocyte sedimentation rate, Richie index, number of 
swollen joints and duration of morning stiffness as 
compared to these parameters at the start of the therapy 
were classified as “good responders”, while those 
showing slight improvement in these indices were 
classified as “poor responders”.  *Corresponding author: e-mail: perwaiz.iqbal@aku.edu 
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Plasma/serum was analyzed for homocysteine using a kit 
method (Abbott Laboratories Ltd; Pakistan), while DNA 
was isolated from the leukocytes using standard 
procedure as described previously (Ali et al., 2006). 
Genotyping protocol for the MTHFR C677T and A1298C 
polymorphisms was based on polymerase chain reaction 
(PCR) followed by restriction fragment length 
polymorphism (RFLP) as described in a previous report 
(Yakub et al., 2012). The study had been approved by the 
Ethics Review Committee of the Aga Khan University. 
  
RESULTS 
  
Mean concentrations of plasma homocysteine in males 
and females were found to be 16.2±3.0 and 13.1±6.7 
µmol/l, respectively. However, mean homocysteine 
concentration in female RA patients was significantly 
higher compared to mean homocysteine concentration in 
general population in Karachi (13.1±6.7 µmol/l vs. 
11.4±5.3 µmol/l; p<0.001; Yakub et al., 2010). Twenty 
eight RA patients were found to be “good responders” to 
MTX, while 23 were identified as “poor responders”. No 
significant differences were observed between “good 
responders” and “poor responders” in terms of gender, 
age, duration of RA and plasma levels of homocysteine 
(table 1). Frequencies of MTHFR 1298C and MTHFR 
677T alleles in RA patients were not significantly 
different from their frequencies in general population in 
Karachi (0.553 vs. 0.55, p=0.977; and 0.196 vs. 0.15; 
p=0.338, respectively), (Yakub et al., 2012). Genotypes 
and allele frequencies of the two polymorphisms were not 
significantly different between “good responders” and 
“poor responders” (table 2). 
  
Table 1: Demographic and clinical characteristics of RA patients on MTX therapy with response to the drug 
 
Variable* Good responders (n=28) Poor responders (n=23) P value** 
Gender 
Males 
Females 
 
5(17.9) 
23(82.1) 
 
3(13.0) 
20(87.0) 
 
0.93 
Age  
(Years)  
 
41.3±10.7 
 
42.4±8.8 
 
0.69 
Duration of RA 
(Years) 
 
6.2±4.8 
 
7.0±4.0 
 
0.53 
Homocysteine  
(µmol/l) 
 
14.1±5.1 
 
14.2±9.0 
 
0.82 
*Values of gender are N (%), while all other values are expressed as mean ±SD. 
**P value compares the percentages in two groups by using Chi-square analysis; while mean values are compared using 
Independent sample t test. P value<0.05 was considered significant. 
 
Table 2: Distribution of genotypes and allele frequencies of single nucleotide polymorphisms (SNPs) of MTHFR in 
“Good responders” and “Poor responders” to MTX therapy 
 
Good responders (n=28) Poor responders (n=23) Polymorphism 
N (%) N (%) P value* 
MTHFR C677T 
Genotypes 
CC 
CT 
TT  
Allele  
C 
T 
 
 
19(67.9) 
7(25.0) 
2(7.1) 
 
45(80.3) 
11(19.7) 
 
 
16(69.6) 
5(21.7) 
2(8.7) 
 
37(80.4) 
9(19.6) 
 
 
0.89 
0.78 
0.75 
 
0.75 
MTHFR A1298C** 
Genotypes 
AA 
               AC  
               CC 
Alleles 
               A 
               C 
 
 
2(7.1) 
19(67.9) 
6(21.4) 
 
23(42.6) 
31(57.4) 
 
 
5(21.7) 
11(47.8) 
7(30.4) 
 
21(45.7) 
25(54.3) 
 
 
0.27 
0.15 
0.46 
 
0.72 
*P value compares the genotypes and allele frequencies between the two groups using Chi-square test. P value<0.05 was considered 
significant. 
**DNA fragment comprising of this polymorphism could not be amplified in one of the samples among “good responders” 
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DISCUSSION 
  
The advent of pharmacogenomics has opened new vistas 
in the treatment of diseases by employing efficacious 
drugs according to the genetic make-up of the patient 
(Ranganathan and McLeod, 2006). MTX in low-dosages 
is a drug of choice in the treatment of RA because it 
exerts its anti-inflammatory effect by inhibiting the 
enzymes in cellular folate and adenosine pathways 
(Ranganathan, 2013). However, long-term use of this drug 
is not without toxic side effects. While quite a few studies 
have shown that efficacy and toxicity of MTX in RA 
patients is influenced by two SNPs (C677T and A1298C) 
in the gene of MTHFR, a key enzyme in folate 
metabolism, several others did not find any association of 
these polymorphisms and MTX toxicity in their 
populations. For example, an association between 
C677T/A1298C polymorphism(s) and MTX toxicity has 
been reported in Spanish, Caucasian American, African-
American and Korean RA patients (Ranganathan et al., 
2008; Plaza-Plaza et al., 2012; Choe et al., 2012). 
However, no association of these polymorphisms with 
increased MTX adverse effects was observed in Indian 
and Briton RA patients (Aggarwal et al., 2006; Owen et 
al., 2012). Lee et al., 2010 carried out a meta-analysis of 
8 studies and found no association of C677T or A1298C 
polymorphisms with MTX toxicity in Asian RA patients. 
The results of these studies conform well to our findings 
that these polymorphisms are not associated with MTX 
toxicity in Pakistani RA patients. Two studies showed 
paradoxical results and reported association of these 
polymorphisms with increased rate of RA remission in 
patients treated with MTX (Berkun et al., 2004; 
Kurzawski et al., 2007). All these reports point towards 
variable response to MTX in RA patients from different 
populations. Frequency of 1298CC genotype in RA 
patients of certain populations has been found to be 
higher than the expected frequency of this genotype in 
general population (Berkun et al., 2004). Moreover, this 
genotype was found to be associated with reduced toxicity 
to MTX (Berkun et al., 2004). However, in Pakistani RA 
patients, the frequency of 1298CC genotype was not 
significantly different from healthy controls (Yakub et al., 
2012). This could be one of the reasons for lack of 
association of A1298C polymorphism in Pakistani RA 
patients.  
  
The mechanism by which MTHFR polymorphisms could 
be causing MTX toxicity in some RA patients is unclear. 
However, the role of increased concentrations of plasma 
homocysteine in RA patients with MTHFR 677CT and 
MTHFR 677TT genotypes cannot be discounted (van Ede 
et al., 2002). Increased levels of homocysteine are known 
to cause endothelial dysfunction, low density lipoprotein 
oxidation and prothrombotic changes (Hernanz et al., 
1999). All these changes can lead to an increase in 
adverse effects of MTX. Our results should be viewed in 
the light of certain limitations of the study. Patients 
enrolled in this study were in a modest number.  
Moreover, follow-up of these patients was for 6 months 
only. The possibility that some of the patients classified 
under “good responders” might develop MTX toxicity on 
a long term follow-up cannot be ignored. In spite of these 
limitations, our data did not show any association of 
MTHFR polymorphisms with efficacy and/or toxicity of 
MTX.  
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